Désiré Collen
From Wikipedia, the free encyclopedia
Désiré Collen (Sint Truiden, Belgium, 21 June 1943-), is a Belgian chemist. He studied chemistry at the Katholieke Universiteit Leuven, and since 2002 he is a professor at the Centre for Molecular en Vascular Biology, and he is also head of the Departement of Transgene Technology and Gene Therapy of the VIB. Together with professor Billiau he discovered tPA in 1979[1]. He is the founder of the Flemish biotech company ThromboGenics. In 1984, he was awarded the Francqui Prize on Biological and Medical Sciences. Together with Peter Carmeliet, he was awarded the Interbrew-Baillet Latour Health Prize in 2005.
[edit] References
- ^ Collen D, Billiau A, Edy J, De Somer P., Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells, Biochim Biophys Acta. 1977 Sep 29;499(2):194-201
[edit] External links
This Belgian biographical article is a stub. You can help Wikipedia by expanding it.
